Head & Neck Cancer Drugs Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2020 – 2030

TABLE OF CONTENTS

Chapter 1        Prefix

1.1    Market Scope

1.2    Report Description

1.3    Research Methodology

1.3.1     Primary Research

1.3.2     Secondary Research

1.3.3     In-house Data Modeling

Chapter 2        Executive Summary

2.1   Global Head & Neck Cancer Drugs Market Year-on-Year Growth, 2021 – 2030 (%)

Chapter 3        Market Outline

3.1    Market Inclination, Trend, Outlook, and Viewpoint

3.2    Market Share Analysis: Company’s Competitive Scenario

3.3    Value Chain Analysis

3.4    Porter’s Five Forces Analysis

3.5    Market Dynamics

3.5.1     Drivers

3.5.1.1     Impact Analysis

3.5.2     Restraints

3.5.2.1     Impact Analysis

3.5.3     Opportunities

Chapter 4        Global Head & Neck Cancer Drugs Market by Drug Class: Market Size and Forecast, 2020 – 2030

4.1    Overview

4.2  Chemotherapy

4.2.1   Current Trend and Analysis

4.2.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

4.2.3   Market Size and Forecast by Region, 2020 – 2030 ($ Billion)

4.3  Immunotherapy

4.3.1   Current Trend and Analysis

4.3.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

4.3.3   Market Size and Forecast by Region, 2020 – 2030 ($ Billion)

4.4  Targeted therapy

4.4.1   Current Trend and Analysis

4.4.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

4.4.3   Market Size and Forecast by Region, 2020 – 2030 ($ Billion)

Chapter 5        Global Head & Neck Cancer Drugs Market by Sales Channel: Market Size and Forecast, 2020 – 2030

5.1  Overview

5.2  Hospital Pharmacies

5.2.1   Current Trend and Analysis

5.2.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

5.2.3   Market Size and Forecast by Region, 2020 – 2030 ($ Billion)

5.3  Drug stores & Retail Pharmacies

5.3.1   Current Trend and Analysis

5.3.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

5.3.3   Market Size and Forecast by Region, 2020 – 2030 ($ Billion)

5.4  Online Stores

5.4.1   Current Trend and Analysis

5.4.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

5.4.3   Market Size and Forecast by Region, 2020 – 2030 ($ Billion)

Chapter 6        Global Head & Neck Cancer Drugs Market by Geography: Market Size and Forecast, 2020 – 2030 

6.1  Overview

6.1.1   Global Epilepsy Market Year-on-Year Growth, by region 2021 – 2030 (%)

6.2  North America

6.2.1   Current Trend and Analysis

6.2.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

6.2.3   U.S.

6.2.3.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.2.3.2        By Drug Class

6.2.3.3        By Sales Channel

6.2.4   Canada

6.2.4.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.2.4.2        By Drug Class

6.2.4.3        By Sales Channel

6.2.5   Mexico

6.2.5.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.2.5.2        By Drug Class

6.2.5.3        By Sales Channel

6.3    Europe

6.3.1   Current Trend and Analysis

6.3.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.3   UK

6.3.3.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.3.2        By Drug Class

6.3.3.3        By Sales Channel

6.3.4   Russia

6.3.4.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.4.2        By Drug Class

6.3.4.3        By Sales Channel

6.3.5   France

6.3.5.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.5.2        By Drug Class

6.3.5.3        By Sales Channel

6.3.6   Italy

6.3.6.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.6.2        By Drug Class

6.3.6.3        By Sales Channel

6.3.7   Germany

6.3.7.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.7.2        By Drug Class

6.3.7.3        By Sales Channel

6.3.8   Rest of Europe

6.3.8.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.3.8.2        By Drug Class

6.3.8.3        By Sales Channel

6.4    Asia-Pacific

6.4.1   Current Trend and Analysis

6.4.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

6.4.3   China

6.4.3.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.4.3.2        By Drug Class

6.4.3.3        By Sales Channel

6.4.4   India

6.4.4.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.4.4.2        By Drug Class

6.4.4.3        By Sales Channel

6.4.5   Japan

6.4.5.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.4.5.2        By Drug Class

6.4.5.3        By Sales Channel

6.4.6   Rest of Asia-Pacific

6.4.6.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.4.6.2        By Drug Class

6.4.6.3        By Sales Channel

6.5    RoW

6.5.1   Current Trend and Analysis

6.5.2   Market Size and Forecast, 2020 – 2030 ($ Billion)

6.5.3   South & Central America

6.5.3.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.5.3.2        By Drug Class

6.5.3.3        By Sales Channel

6.5.4   Middle East

6.5.4.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.5.4.2        By Drug Class

6.5.4.3        By Sales Channel

6.5.5   Africa

6.5.5.1        Market Size and Forecast, 2020 – 2030 ($ Billion)

6.5.5.2        By Drug Class

6.5.5.3        By Sales Channel

Chapter 7        Company Profiles

7.1  Bristol-Myers Squibb Company.

7.1.1     Company Overview

7.1.2     Product Portfolio

7.1.3     Business Strategies

7.1.4     Financials

7.1.5     Recent Developments

7.2  AstraZeneca PLC.

7.2.1     Company Overview

7.2.2     Product Portfolio

7.2.3     Business Strategies

7.2.4     Financials

7.2.5     Recent Developments

7.3  Eli Lilly and Company (ARMO Biosciences)

7.3.1     Company Overview

7.3.2     Product Portfolio

7.3.3     Business Strategies

7.3.4     Financials

7.3.5     Recent Developments

7.4  F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

7.4.1     Company Overview

7.4.2     Product Portfolio

7.4.3     Business Strategies

7.4.4     Financials

7.4.5     Recent Developments

7.5  Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)

7.5.1     Company Overview

7.5.2     Product Portfolio

7.5.3     Business Strategies

7.5.4     Financials

7.5.5     Recent Developments

7.6  AstraZeneca PLC

7.6.1     Company Overview

7.6.2     Product Portfolio

7.6.3     Business Strategies

7.6.4     Financials

7.6.5     Recent Developments

7.7  Immutep Limited

7.7.1     Company Overview

7.7.2     Product Portfolio

7.7.3     Business Strategies

7.7.4     Financials

7.7.5     Recent Developments

7.8  Novartis AG

7.8.1     Company Overview

7.8.2     Product Portfolio

7.8.3     Business Strategies

7.8.4     Financials

7.8.5     Recent Developments

7.9  Merck KGaA (EMD Serono, Inc.)

7.9.1     Company Overview

7.9.2     Product Portfolio

7.9.3     Business Strategies

7.9.4     Financials

7.9.5     Recent Developments

7.10   Pfizer Inc.

7.10.1   Company Overview

7.10.2   Product Portfolio

7.10.3   Business Strategies

7.10.4   Financials

7.10.5   Recent Developments

7.11   Merck & Co., Inc.

7.11.1   Company Overview

7.11.2   Product Portfolio

7.11.3   Business Strategies

7.11.4   Financials

7.11.5   Recent Developments

7.12   Others

7.12.1   Company Overview

7.12.2   Product Portfolio

7.12.3   Business Strategies

7.12.4   Financials

7.12.5   Recent Developments